



KABRADRUGSLIMITED

CIN-L02423MP1989PLC005438

To
Listing Department
BSE Ltd,
P.J. Tower, Dalal Street, Mumbai –
400 001.

14th November 2022

In compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 please find attached herewith unaudited financial result for quarter ended 30th September 2022

Kindly acknowledge the receipt and take the same on your record.

Thanking you,

For Kabra Drugs Limited



Authorised Signatory

REGD OFFC: SHOP NO. 270, SHASTRI MARKET, INDORE M.P.

PHONE NO 0731-4247626

Email – kabradrugs@gmail.com, [website- www.kabradrugs.com](http://www.kabradrugs.com)

Kabra Drugs Ltd.

CIN:- L02423MP1989PLC005438

Regd. Office: Shop No. 270, Shastri Market, Indore - 452001 Email:-
kabradrugs@gmail.com

Statement of Audited Financial Results for the Quarter & Half Year Ended September 30, 2022

		Quarter Ended			Six Months Ended		(Rs. In lacs)
Sl no.	Particulars	30-Sep-22	30-Jun-22	30-Sep-21	30-Sep-22	30-Sep-21	Year Ended 31 Mar 2022
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	INCOME						
(a)	Revenue From Operation Other	-	-	-	-	-	-
(b)	Income	0.64	-	-	0.64	-	-
	Total Income from Operations (Net)	0.64	-	-	0.64	-	-
2	EXPENSES						
(a)	Cost of material consumed						
(b)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade			-			
(c)	Employee benefit expense						
(d)	Finance Costs	-	-	1.06	-	-	-
(e)	Depreciation and amortization expense	-	5.04	-	10.44	2.56	8.93
(f)	Other expenses(Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	5.40	-	-	-	-	-
	Total Expenses	1.35	2.34	1.75	3.69	6.41	8.61
		6.75	7.38	2.81	14.13	8.97	18.54
3	Profit / (Loss) from operations before exceptional items Tax (1-2)	(6.11)	(7.38)	(2.81)	(13.49)	(8.97)	(18.54)
4	Exceptional Items	-	-	-	-	-	-
5	Profit / (Loss) before Tax (3 ± 4)	(6.11)	(7.38)	(2.81)	(13.49)	(8.97)	(18.54)
6	Tax Expense	-	-	-	-	-	-
7	Net Profit / (Loss) after Tax (5 - 6)	(6.11)	(7.38)	(2.81)	(13.49)	(8.97)	(18.54)
8	Other Comprehensive Income (net of tax)	-	-	-	-	-	-
9	Total Comprehensive Income for the period (7 ± 8)	(6.11)	(7.38)	(2.81)	(13.49)	(8.97)	(18.54)
10	Paid-up equity share capital (Face Value of Rs.10/- each)	438.86	438.86	438.86	438.86	438.86	438.86
11	Other Equity	-	-	-	-	-	(478.17)
12	Earnings Per Share (of Rs. 10/- each) (not annualised):						
(a)	Basic	(0.14)	(0.17)	(0.06)	(0.31)	(0.20)	(0.42)
(b)	Diluted	(0.14)	(0.17)	(0.06)	(0.31)	(0.20)	(0.42)



Kabra Drugs Ltd.

CIN:- L02423MP1989PLC005438
Regd. Office: Shop No. 270, Shastri Market, Indore - 452001
Email:- kabradrugs@gmail.com

(Rs. in Lakhs)

Standalone Statement of Assets and Liabilities		As at 30th September, 2022	As at 31st March, 2022
Particulars		Un-Audited	Audited
A	ASSETS		
1	Non-current assets		
	Property, plant and equipment	-	-
	Capital work-in-progress	-	-
	Other intangible assets	-	-
	Investments in subsidiaries, associates and joint ventures	-	-
	Financial assets		
	Investments	-	-
	Loans	-	-
	Other financial assets	-	-
	Income Tax assets (net)	-	-
	Deferred tax assets (net)	-	-
	Other non-current assets	2.32	2.32
	Sub-total - Non-Current Assets	2.32	2.32
2	Current assets		
	Inventories	-	-
	Financial assets		
	Investments	-	-
	Trade receivables	60.05	60.05
	Cash and cash equivalents	-	0.04
	Bank balances other than Cash and Cash equivalents above	0.10	0.09
	Loans, Current	5.35	7.13
	Other financial assets	-	-
	Other current assets	3.34	3.34
	Assets classified as held for sale	-	-
	Sub-total - Current Assets	68.84	70.65
	TOTAL - ASSETS	71.16	72.97
B	EQUITY AND LIABILITIES		
1	Equity		
	Equity Share capital	438.86	438.86
	Other equity	(491.66)	(478.17)
	Sub-total - Shareholders' funds	(52.80)	(39.31)
2	LIABILITIES		
	Non-current liabilities		
	Financial liabilities		
	Borrowings, non-Current	-	-
	Provisions	-	-
	Income tax liabilities (net)	-	-
	Other non-current liabilities	-	-
	Sub-total - Non-current liabilities	-	-
3	Current liabilities		
	Financial liabilities		
	Borrowings, Current	114.37	102.58
	Trade payables, Current	-	-
	Other financial liabilities	-	-
	Other current liabilities	9.59	9.70
	Provisions	-	-
	Current tax liabilities (net)	-	-
	Sub-total - Current liabilities	123.96	112.28
	TOTAL - EQUITY AND LIABILITIES	71.16	72.97



Kabra Drugs Ltd.

CIN:- L02423MP1989PLC005438

Regd. Office: Shop No. 270, Shastri Market, Indore - 452001 Email:-
kabradrugs@gmail.com

Notes:

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 14, 2022.
- 2 The Statutory Auditors have carried out a limited review of the above financial result. 3 Company has only one segment and hence no separate segment result has been given.
- 4 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
- 5 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 By order of the Board For, Kabra Drugs Ltd.

Place : Indore

Date : 14th November, 2022



K. R. Singh
Director/Compliance Officer

Kabra Drugs Ltd.

CIN:- L02423MP1989PLC005438

Regd. Office: Shop No. 270, Shastri Market, Indore - 452001

STANDALONE STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED 30 SEPTEMBER 2022

(Rs. in Lakhs, unless otherwise stated)

Particulars	30.09.2022	30.09.2021
	Rupees	Rupees
A. CASH FLOW FROM OPERATING ACTIVITIES:		
Profit before tax	- 13.49	- 8.97
Adjustment For :		
Share of (profit)/loss from investment in partnership	-	-
Depreciation/amortization on continuing operation	-	-
Pre-operating Expense	-	-
Interest expenses	-	-
Operating profit before working capital changes	- 13.49	- 8.97
Movement in Working Capital :		
Increase/(decrease) in Inventory	-	-
Increase/(decrease) in Trade receivables	-	-
Increase/(decrease) in Short Term Loan & Advances	1.78	-
Increase/(decrease) in Current Liabilities	0.11	4.58
Increase/(decrease) in Trade Payable	-	-
Increase/(decrease) in Other Current Assets	-	-
Direct taxes paid (net of refunds)	-	-
Net Cash Flow from Operating Activities(A)	- 11.82	- 4.39
B. CASH FLOW FROM INVESTING ACTIVITIES		

Lib ulh



b.v. Jy





RISHI SEKHRI AND ASSOCIATES

CHARTERED ACCOUNTANTS

GROUND FLOOR, BANDRA ARCADE BUILDING, OPP. RAILWAY STATION, BANDRA (WEST), MUMBAI - 400 050.
Tel.: 9820501848 Email : rishisekhri@gmail.com

Limited Review Report on unaudited standalone financial results of **Kabra Drugs Limited** for the quarter ended 30 September 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Kabra Drugs Limited

1. We have reviewed the accompanying Statement for unaudited standalone financial results of **Kabra Drugs Limited** for the quarter ended 30 September 2022 ("the Statement") being submitted pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (Listing Regulations').
2. This Statement, which is the responsibility of the management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and is substantially less than the audit conducted in accordance with the standards on Auditing Specified under section 143(10) of the Act, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards, i.e. Ind AS 34 as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies, has not disclosed the Information required to be disclosed in terms of Regulation 33 of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, of that it contains any material misstatement.

FOR, RISHI SEKHRI AND ASSOCIATES,
Chartered Accountants
FRN: 126216W

CA RISHI SEKHRI
Partner
MEMBERSHIP NO.126656

Place:-MUMBAI
Date:-14.11.2022
UDIN: 22126656BDBUDW2952

